Cancer News
Cancer Education and Research Institute® (CERI)'s Cancer Education Programs
Our Team of cancer experts at Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
Personalized Cancer Therapy
New type of CRISPR gene editing technology first ever tested in patients with cancer
Aygün Sahin, MSc, PhD | CEO, President, and Cancer Lead, Cancer Education and Research Institute (CERI)
One dose could potentially provide life-long protection against cancer recurrence.
For the first time, scientists have used CRISPR gene editing technology to insert genes that allow immune cells to direct their attack on cancer cells, potentially leaving normal cells unharmed and increasing the effectiveness of immunotherapy.
The CRISPR technique has been previously used in humans to remove specific genes to allow the immune system to be more activated against cancer.
What is different in this study is that, researchers showed for the first time that using CRISPR they can not only take out specific genes, but also to insert new ones in immune cells to efficiently redirecting the immune cells to recognize mutations in the patient’s own cancer cells and then kill cancer cells.
The researchers report treating 16 patients with a variety of solid cancers including colon, breast and lung cancers.
First, blood was isolated from patients based on their binding to capture reagents that displayed up to 350 mutations from the patient’s own cancer, for a total of over 5000 mutations being targeted across the 34 characteristics of HLA subtypes of the immune system.
The genes of the immune receptors on the patient’s T cells that allowed the immune cells to specifically recognized the cancer mutations were then sequenced, totaling 175 newly isolated cancer-specific immune receptors.
These genes were then replaced (by cutting out and then inserting using CRISPR) with the code for a gene that recognized proteins on their cancer.
Removing the existing code before inserting a new one was critical to ensure that the new genetic code did not create a safety problem.
The T cell receptor is made up of two protein chains. Combining one of the protein chains from the patient’s original code with the chain from the newly inserted one, could create a new receptor that the body might not recognize.
Up to three of these preparations of gene edited immune cells were infused back to the patients after giving conditioning chemotherapy.
A total of 37 immune receptors being infused to the 16 patients participating in this research.
The gene edited immune cells were preferentially recovered from biopsies of patient’s post-infusion,with the representation of the top 20% of immune cells in the cancer.
“This study demonstrates the feasibility of isolating and cloning multiple immune cell receptors recognizing mutations in cancer cells, the simultaneous knock-out of the endogenous immune receptor and knock-in of the redirecting immune receptor using single-step, non-viral precision genome editing, the manufacturing of CRISPR engineered T cells at clinical grade, the safety of infusing up to three gene edited immune cell products, and the ability of the gene edited immune cells to traffic to the patients’ tumors,” said Dr. Antoni Ribas, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center and professor of medicine at UCLA, co-leader of the study.
This study is a collaboration between PACT Pharma and UCLA.
For the first time, scientists have used CRISPR gene editing technology to insert genes that allow immune cells to direct their attack on cancer cells, potentially leaving normal cells unharmed and increasing the effectiveness of immunotherapy.
The CRISPR technique has been previously used in humans to remove specific genes to allow the immune system to be more activated against cancer.
What is different in this study is that, researchers showed for the first time that using CRISPR they can not only take out specific genes, but also to insert new ones in immune cells to efficiently redirecting the immune cells to recognize mutations in the patient’s own cancer cells and then kill cancer cells.
The researchers report treating 16 patients with a variety of solid cancers including colon, breast and lung cancers.
First, blood was isolated from patients based on their binding to capture reagents that displayed up to 350 mutations from the patient’s own cancer, for a total of over 5000 mutations being targeted across the 34 characteristics of HLA subtypes of the immune system.
The genes of the immune receptors on the patient’s T cells that allowed the immune cells to specifically recognized the cancer mutations were then sequenced, totaling 175 newly isolated cancer-specific immune receptors.
These genes were then replaced (by cutting out and then inserting using CRISPR) with the code for a gene that recognized proteins on their cancer.
Removing the existing code before inserting a new one was critical to ensure that the new genetic code did not create a safety problem.
The T cell receptor is made up of two protein chains. Combining one of the protein chains from the patient’s original code with the chain from the newly inserted one, could create a new receptor that the body might not recognize.
Up to three of these preparations of gene edited immune cells were infused back to the patients after giving conditioning chemotherapy.
A total of 37 immune receptors being infused to the 16 patients participating in this research.
The gene edited immune cells were preferentially recovered from biopsies of patient’s post-infusion,with the representation of the top 20% of immune cells in the cancer.
“This study demonstrates the feasibility of isolating and cloning multiple immune cell receptors recognizing mutations in cancer cells, the simultaneous knock-out of the endogenous immune receptor and knock-in of the redirecting immune receptor using single-step, non-viral precision genome editing, the manufacturing of CRISPR engineered T cells at clinical grade, the safety of infusing up to three gene edited immune cell products, and the ability of the gene edited immune cells to traffic to the patients’ tumors,” said Dr. Antoni Ribas, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center and professor of medicine at UCLA, co-leader of the study.
This study is a collaboration between PACT Pharma and UCLA.
References:
- First use of CRISPR to substitute genes to treat patients with cancer. https://www.newswise.com/articles/first-use-of-crispr-to-substitute-genes-to-treat-patients-with-cancer (accessed 11/22/2022)
- CRISPR For Cancer Takes a Big Step Forward. https://time.com/6232260/crispr-cancer-treatment (accessed 11/22/2022)
- New CRISPR cancer treatment tested in humans for first time. https://www.freethink.com/health/crispr-cancer-treatment (accessed 11/22/2022)
Do you need help with cancer diagnosis?
Please fill the application form on our CERI Personalized Patient Program page - we CAN help you!
#Empowermentagainstcancer™ #CERICancerEducation #CERICares #CancerSimplified
#cancer #glioblastoma #gbm #glioblastomatherapy #GBMtherapy #glioblastomatreatment #GBMtreatment #cancereducation #cancerresearch #cancertreatment #canceredinstitute
GET YOUR FREE ARTICLE: Make sure to get your free article as our gift to you! Go to: canceredinstitute.org/ceri-simplified-cancer-research-articles
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
- INSTAGRAM: instagram.com/canceredinstitute
- FACEBOOK: facebook.com/canceredinstitute
- Twitter: twitter.com/canceredinst
- LinkedIn: linkedin.com/company/canceredinstitute
You might also like:
|
|
|
Disclaimer: We can not assume responsibility of misinterpretation of content.
Please donate to support our program - help us save MORE lives!
